All issues > Volume 35(6); 1992

Case Report

J Korean Pediatr Soc. 1992;35(6):822-828. Published online June 15, 1992.

Two Cases of Doxorubicin-induced Dilated Cardiomyopathy

Jin Won JW Park¹, Kyeong Ah KA Lee¹, Yong Woon YW Paik¹, Hyun Kee HK Chung¹, Jae Sun JS Park¹

¹Department of Pediatrics, Kosin Medical College, Pusan, Korea

Abstract

Doxorubicin is an anthracycline antibiotic with a broad spectrum of activity in human neoplasms. However, this agent may cause, frequently, irreversible congestive left ventricular failure. We have experienced 2 cases of doxorubicin induced cardiomyopathy in one patient with multiple eosinophilic granuloma and another patient with T cell leukemia. Total dosage of doxorubicin was 295 mg/M2 for the 6 months duration and 500 mg/M2 for the 23 months in each cases. Though, we haven't performed radionuclide angiocardiomyopathy or endomyocardial biopsy, echocardiographic findings of increased LVID, decreased shortening fraction and decreased ejection fraction were compatable with doxorubicin induced cardiomyopathy in both cases. In the first case, general condition of pateint and sign of heart failure were not noticably improved by digoxin and lasix. But, with addition of prednisolone, the patient improved remarkably in symptom and sign of heart failure. In the second case, edema, hepatomegaly and cardiomegaly were improved by pericardiocentesis, and lasix. The patient, however, died of relapsed leukemia in bone marrow and CNS about 3 months later.

Keywords :Doxorubicin, Dilated cardiomypathy